Edition:
United States

Endocyte Inc (ECYT.O)

ECYT.O on Nasdaq

1.40USD
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
$1.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
502,551
52-wk High
$3.49
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Endocyte Q2 loss per share $0.28
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Endocyte Inc :Endocyte reports second quarter financial results and provides clinical and pipeline update.Q2 loss per share $0.28.Endocyte - ‍plans to initiate clinical development for Car T-Cell program in osteosarcoma in 2018; IND filed for dual-targeted DNA crosslinker EC2629​.Endocyte - sees cash, cash equivalents balance at end of 2017 about $105 million; full expense impact of restructuring expected to be realized by end of Q4.  Full Article

Endocyte announces clinical updates for EC1456 and EC1169
Friday, 2 Jun 2017 08:02am EDT 

June 2 (Reuters) - Endocyte Inc ::Endocyte announces clinical updates for EC1456 and EC1169.Endocyte Inc - continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and of EC1169 in taxane-naïve patients.Endocyte Inc - ‍restructuring to reduce workforce by approximately 40%; will maintain core competencies and preserve capital for highest priority programs​.Endocyte Inc - refocusing efforts on chimeric antigen receptor t-cell (car t-cell) and dual-targeted dna crosslinker drug ec2629 programs.Endocyte Inc - ‍endocyte will stop enrollment of taxane-naïve mcrpc patients in ec1169 trial​.Endocyte Inc - plans to stop enrollment in ec1456 trial.Endocyte Inc says anticipates one-time charges of approximately $2.4 million related to termination benefits and accelerated closure of ec1456 trial.Endocyte inc says as a result of this restructuring, company is revising its guidance for 2017.Endocyte inc - company plans to file its IND for ec2629 in mid-2017, which includes a potent DNA-targeted warhead with clinically proven activity.Endocyte - will narrow ec1169 development program to focus only on cohort of taxane-exposed, metastatic castration-resistant prostate cancer patients.Endocyte inc - anticipates one-time charges of approximately $2.4 million related to termination benefits and accelerated closure of ec1456 trial.Endocyte inc says now expects its cash balance at end of 2017 to be approximately $105 million.  Full Article

Endocyte Q1 loss per share $0.27
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Endocyte Inc :Endocyte reports first quarter financial results and provides clinical and pipeline update.Q1 loss per share $0.27.Q1 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Endocyte inc - anticipates its cash balance at end of 2017 to be approximately $100 million.  Full Article

Endocyte Q4 loss per share $0.26
Friday, 10 Mar 2017 08:05am EST 

Endocyte Inc : Endocyte reports fourth quarter and year end 2016 financial results and provides clinical and pipeline update . Q4 loss per share $0.26 . Q4 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Endocyte inc- anticipates its cash balance at end of 2017 to be approximately $100 million . Endocyte inc- also anticipate receiving additional clinical data on ec1169 and ec1456, during 2017 .Endocyte inc- expect to file investigational new drug application for ec2629 in mid 2017.  Full Article

Endocyte plans to collaborate with Seattle Children's Research Institute
Friday, 10 Mar 2017 08:00am EST 

Endocyte Inc :Endocyte Inc - plan to collaborate with seattle children's research institute and Dr. Michael Jensen for development of Endocyte's SMDC platform.  Full Article

Endocyte reports Q2 loss per share $0.33
Thursday, 4 Aug 2016 04:01pm EDT 

Endocyte Inc : Q2 loss per share $0.33 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Endocyte reports second quarter 2016 financial results .Company revised guidance for its expected cash balance at end of 2016 to be above $130 million.  Full Article

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update